Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

Phase 1CompletedNCT00261937

Bnai Zion Medical Center

Overview

We hypothesize that inhaled Furosemide will be an effective treatment in infants with acute bronchiolitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Bronchiolitis

Interventions

Inhaled Furosemide vs Placebo (Normal Saline)DRUG

Eligibility

Sex: ALLMin age: 1 DayMax age: 12 Months

Medical Language ↔ Plain English

Inclusion Criteria: * Age: 0-12 months. * Infants who are otherwise healthy * Infants with chronic lung disease of prematurity (BPD) will be included, but will be analyzed separately. * Parents signed a written informed consent. Exclusion Criteria: * • Other previous or co-morbidity, specifically: respiratory (other than BPD, like Asthma or Cystic Fibrosis), cardiac or renal disease or anomaly.

Locations (1)

Bnai Zion Medical Center and Naharia Galilli Medical Center

Haifa, Israel

Outcomes

Primary Outcomes

Clinical respiratory effects

Secondary Outcomes

1. The duration of hospitalization

2. Time weaned off oxygen

3. Time to full enteral feeding

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.